CAS NO: | 896705-16-1 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 360.41 |
---|---|
Formula | C21H20N4O2 |
CAS No. | 896705-16-1 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 5 mg/mL (13.9 mM) |
Water: <1 mg/mL | |
Ethanol: 2 mg/mL (5.5 mM) | |
Other Info | Exact Mass: 362.1743 Chemical Name: N-(2-(dimethylamino)ethyl)-12-oxo-11a,12-dihydro-5aH-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide SMILES Code: O=C(C1=CC=CN2C1=NC3C=C(C=CC=C4)C4=CC3C2=O)NCCN(C)C |
Synonyms | BMH 21; BMH-21; BMH21; |
In Vitro | In vitro activity: BMH-21 causes proteasome-dependent destruction of RPA194, the large catalytic subunit protein of Pol I holocomplex. In U2OS cancer cell line, BMH-21 results in degradation of RPA194 and translocation of NCL with IC50 of 0.05 μM and 0.07 μM, respectively. By causing nucleolar stress, BMH-21 also shows potent inhibition on cell viability. Cell Assay: The cells (U2OS osteosarcoma cells) are maintained at 37 °C in a humidified atmosphere containing 5% CO2. U2OS osteosarcoma cells are cultured in DMEM supplemented with 15% fetal bovine serum. Cells are plated in 96-well plates at a density of 10000 cells/well in triplicate and incubated for 48 h with the compounds. Viability is determined using WST-1 cell proliferation reagent. |
---|---|
In Vivo | BMH-21 reduces tumor growth in mouse xenografts. |
Animal model | Mouse |
Formulation & Dosage | 25 mg/kg; 50 mg/kg; injection |
References | Cancer Cell. 2014 Jan 13;25(1):77-90; J Med Chem. 2014 Jun 12;57(11):4950-61. |